Unique ID issued by UMIN | UMIN000009312 |
---|---|
Receipt number | R000010934 |
Scientific Title | Serum concentration of vascular endothelial growth factor of patients with chorioretinal diseases before and after the anti-vascular endothelial growth factor therapy |
Date of disclosure of the study information | 2012/11/11 |
Last modified on | 2019/05/17 20:10:55 |
Serum concentration of vascular endothelial growth factor of patients with chorioretinal diseases before and after the anti-vascular endothelial growth factor therapy
Serum VEGF with chorioretinal diseases before and after the anti-VEGF therapy
Serum concentration of vascular endothelial growth factor of patients with chorioretinal diseases before and after the anti-vascular endothelial growth factor therapy
Serum VEGF with chorioretinal diseases before and after the anti-VEGF therapy
Japan |
diabetic retinopathy, central retinal vein occlusion, branch retinal vein occlusion, age-related macular degeneration, myopic choroidal neovascularization, idiopathic choroidal neovascularization
Ophthalmology |
Others
NO
To investigate the general effect of anti-vascular endothelial growth factor therapy by measuring of serum concentration of vascular endothelial growth factor of patients with chorioretinal diseases before and after the intravitreal injection of anti-vascular endothelial growth factor
Pharmacokinetics
Confirmatory
Pragmatic
Not applicable
The change of the serum concentration of vascular endothelial growth factor before, 1 week,1 month and 2 months after the injection of anti-vascular endothelial growth factor
The correlation of best corrected visual acuity or central retinal subfield thickness and serum concentration of vascular endothelial growth factor before, 1 week and 1 month after the injection of anti-vascular endothelial growth factor
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Observation period: 1 month
Number of treatment: 1
Amount of treatment and method: intravitreal injection of ranibizumab (0.5mg/0.05ml) or bevacizumab (1.25mg/0.05ml) or aflibercept (2mg/0.05ml)
20 | years-old | <= |
Not applicable |
Male and Female
Patient with active disease, male or female, people 20 years old or older, with informed concent
Patients without active disease,
severe glaucoma, inflammation eye disease, without informed concent
100
1st name | Masahito |
Middle name | |
Last name | Ohji |
Shiga University of Medical Science
Department of Ophthalmology
520-2192
Seta Tsukinowa-cho, Otsu, Shiga, JAPAN 520-2192
077-548-2276
ohji@belle.shiga-med.ac.jp
1st name | Tomoko |
Middle name | |
Last name | Sawada |
Shiga University of Medical Science
Department of Ophthalmology
520-2192
Seta Tsukinowa-cho, Otsu, Shiga, JAPAN 520-2192
077-548-2276
tsawada@belle.shiga-med.ac.jp
Department of Ophthalmology, Shiga University of Medical Science
Ministry of Education, Culture, Sports, Science and Technology
Japanese Governmental office
Research Ethics Committe of Shiga Univercity of Medical Science
SetaTsukinowa cho, Otsu, JAPAN
0775483576
hqrec@belle.shiga-med.ac.jp
NO
滋賀医科大学附属病院(滋賀県)
2012 | Year | 11 | Month | 11 | Day |
Unpublished
Completed
2012 | Year | 10 | Month | 30 | Day |
2017 | Year | 07 | Month | 20 | Day |
2012 | Year | 11 | Month | 11 | Day |
2018 | Year | 03 | Month | 31 | Day |
2018 | Year | 06 | Month | 30 | Day |
2018 | Year | 09 | Month | 30 | Day |
2018 | Year | 12 | Month | 31 | Day |
2012 | Year | 11 | Month | 11 | Day |
2019 | Year | 05 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010934
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |